AB Science's masitinib combined with riluzole demonstrated a 42.3% five-year survival rate in ALS patients, with 52.9% among those without baseline functional loss. These outcomes substantially exceed historical registry benchmarks of 7-27.8%, suggesting a meaningful therapeutic advance for a rapidly progressive neurodegenerative condition.
Key Points
- 42.3% five-year survival rate with masitinib-riluzole combination therapy
- 49% of long-term survivors maintained quality of life without mechanical assistance
- Identified biomarker may predict individual treatment response in ALS
Longevity Analysis
ALS progression involves cascading failure across multiple systems—motor control, energy production at the cellular level, and the capacity to maintain basic physiological functions. The significant survival extension and preservation of functional independence in this trial suggests that targeted intervention in the disease pathway can substantially alter the trajectory of neurodegeneration. The emerging biomarker offers the possibility of stratifying patients, allowing treatment allocation based on individual biological signatures rather than population-level assumptions. This approach reflects a deeper understanding of why some patients benefit while others do not, creating the opportunity to match therapy to individual physiology rather than treating all ALS patients identically.
Original published by Longevity.Technology.